Michael Bittner
Overview
Explore the profile of Michael Bittner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2046
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Grimm F, Iwata Y, Sirenko O, Bittner M, Rusyn I
Assay Drug Dev Technol
. 2015 Nov;
13(9):529-46.
PMID: 26539751
Cell-based high-content screening (HCS) assays have become an increasingly attractive alternative to traditional in vitro and in vivo testing in pharmaceutical drug development and toxicological safety assessment. The time- and...
12.
Mohsenizadeh D, Hua J, Bittner M, Dougherty E
BMC Bioinformatics
. 2015 Oct;
16 Suppl 13:S3.
PMID: 26423606
Background: Most dynamical models for genomic networks are built upon two current methodologies, one process-based and the other based on Boolean-type networks. Both are problematic when it comes to experimental...
13.
Whitsett T, Mathews I, Cardone M, Lena R, Pierceall W, Bittner M, et al.
Mol Cancer Res
. 2014 Jan;
12(4):550-9.
PMID: 24469836
Unlabelled: Insensitivity to standard clinical interventions, including chemotherapy, radiotherapy, and tyrosine kinase inhibitor (TKI) treatment, remains a substantial hindrance towards improving the prognosis of patients with non-small cell lung cancer...
14.
Jung S, Verdicchio M, Kiefer J, Von Hoff D, Berens M, Bittner M, et al.
BMC Genomics
. 2013 Feb;
14:110.
PMID: 23418942
Background: Identifying similarities and differences in the molecular constitutions of various types of cancer is one of the key challenges in cancer research. The appearances of a cancer depend on...
15.
Yarger J, Babine R, Bittner M, Shanle E, Xu W, Hershberger P, et al.
J Mol Endocrinol
. 2012 Nov;
50(1):43-57.
PMID: 23132914
Ligand structure can affect the activation of nuclear receptors, such as estrogen receptors (ERs), and their control of signaling pathways for cellular responses including death and differentiation. We hypothesized that...
16.
Ferrari U, Exner T, Wanka E, Bergemann C, Meyer-Arnek J, Hildenbrand B, et al.
Int J Biometeorol
. 2011 Feb;
56(1):137-43.
PMID: 21301889
Chronic obstructive pulmonary disease (COPD) is one of the most important causes of morbidity and mortality in the world. The disease is often aggravated by periods of increased symptoms requiring...
17.
Layek R, Datta A, Bittner M, Dougherty E
Bioinformatics
. 2011 Jan;
27(4):548-55.
PMID: 21193523
Motivation: Cancer encompasses various diseases associated with loss of cell cycle control, leading to uncontrolled cell proliferation and/or reduced apoptosis. Cancer is usually caused by malfunction(s) in the cellular signaling...
18.
Von Hoff D, Stephenson Jr J, Rosen P, Loesch D, Borad M, Anthony S, et al.
J Clin Oncol
. 2010 Oct;
28(33):4877-83.
PMID: 20921468
Purpose: To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which...
19.
Sekulic A, Kim S, Hostetter G, Savage S, Einspahr J, Prasad A, et al.
Cancer Prev Res (Phila)
. 2010 Sep;
3(10):1277-83.
PMID: 20876729
Cutaneous squamous cell carcinoma (SCC) occurs commonly and can metastasize. Identification of specific molecular aberrations and mechanisms underlying the development and progression of cutaneous SCC may lead to better prognostic...
20.
Hanczar B, Hua J, Sima C, Weinstein J, Bittner M, Dougherty E
Bioinformatics
. 2010 Feb;
26(6):822-30.
PMID: 20130029
Motivation: The receiver operator characteristic (ROC) curves are commonly used in biomedical applications to judge the performance of a discriminant across varying decision thresholds. The estimated ROC curve depends on...